950
Xiang SK, et al. Sci China Chem July (2013) Vol.56 No.7
131.7, 129.7, 128.2, 127.4, 126.9, 126.2, 125.9, 125.7,
125.4, 125.2, 34.6, 31.5; MS (70 eV), m/z (%): 260.0 (100)
[M]+.
2-(3-Chlorophenyl)acetaldehyde (46.4 mg, 0.3 mmol) and
phenylacetylene (36.7 mg, 0.36 mmol), BF3·Et2O (2.1 mg,
0.015 mmol) and DCE (1 mL) were mixed in a Schlenck
tube. The reaction mixture was stirred for 15 h at 80 °C. The
solution was cooled to room temperature and the solvent
was removed under vacuum. The crude product was puri-
fied by column chromatography on silica gel (eluent: petro-
leum ether/dichloromethane, v/v = 70:1) to afford 21.4 mg
1-(4-Bromophenyl)naphthalene (3ad)
1
(30%) of 3ga (3ga-1/3ga-2 = 61/39). 3ga-1: H NMR (400
MHz, CDCl3, ppm) 7.867 (d, J = 2.0 Hz, 1H), 7.82 (d, J =
8.8 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.55–7.39 (m, 7H),
7.34 (dd, J1 = 9.6 Hz, J2 = 2.0 Hz, 1H); 13C NMR (100 MHz,
CDCl3, ppm) 140.4, 140.2, 134.5, 131.6, 129.93, 129.0,
128.3, 127.8, 127.5, 127.1, 126.8, 126.7, 126.5; MS (70 eV),
Phenylacetaldehyde (36.0 mg, 0.3 mmol) and 1-bromo-4-
ethynylbenzene (65.2 mg, 0.36 mmol), BF3·Et2O (8.2 mg,
0.06 mmol) and PhCl (1 mL) were mixed in a Schlenck tube.
The reaction mixture was stirred for 15 h at 110 °C. The
solution was cooled to room temperature and the solvent
was removed under vacuum. The crude product was puri-
fied by column chromatography on silica gel (eluent: petro-
leum ether/dichloromethane, v/v = 70:1) to afford 46.7 mg
(55%) of 3ad. IR(KBr) νmax 3058, 2924 cm1; 1H NMR (400
MHz, CDCl3, ppm) 7.90–7.81 (m, 3H), 7.61–7.58 (m, 2H),
7.49–7.47 (m, 2H), 7.44–7.41 (m, 1H), 7.35–7.33 (m, 3H);
13C NMR (100 MHz, CDCl3, ppm) 139.6, 138.9, 133.7,
131.7, 131.4, 131.3, 128.3, 128.0, 126.8, 126.2, 125.9, 125.6,
125.3, 121.4; MS (70 eV), m/z (%): 282.2 (100) [M]+.
1
m/z (%): 237.7 (100) [M]+. 3ga-2: H NMR (400 MHz,
CDCl3, ppm) 7.88–7.82 (m, 2H), 7.52–7.47 (m, 2H),
7.41–7.32 (m, 7H); 13C NMR (100 MHz, CDCl3, ppm)
143.5, 139.5, 136.0, 131.4, 131.0, 129.6, 129.4, 128.7,
128.6, 128.2, 127.2, 126.7, 125.6, 125.4; MS (70 eV), m/z
(%): 238.7 (100) [M]+.
6-Methyl-1-phenylnaphthalene (3ha-1) and 1-methyl-8-phen-
ylnaphthalene (3ha-2)
1-(4-Fluorophenyl)naphthalene (3ae)
2-m-Tolylacetaldehyde (40.2 mg, 0.3 mmol) and
phenylacetylene (36.7 mg, 0.36 mmol), BF3·Et2O (2.1 mg,
0.015 mmol) and DCE (1 mL) were mixed in a Schlenck
tube. The reaction mixture was stirred for 15 h at 80 °C. The
solution was cooled to room temperature and the solvent
was removed under vacuum. The crude product was puri-
fied by column chromatography on silica gel (eluent: petro-
leum ether/dichloromethane, v/v = 70:1) to afford 28.8 mg
Phenylacetaldehyde (36.0 mg, 0.3 mmol) and 1-ethynyl-4-
fluorobenzene (43.2 mg, 0.36 mmol), BF3·Et2O (8.4 mg,
0.06 mmol) and PhCl (1 mL) were mixed in a Schlenck tube.
The reaction mixture was stirred for 15 h at 110 °C. The
solution was cooled to room temperature and the solvent
was removed under vacuum. The crude product was puri-
fied by column chromatography on silica gel (eluent: petro-
leum ether/dichloromethane, v/v = 70:1) to afford 40.6 mg
(61%) of 3ae. IR(KBr) νmax 3042, 2929, 2850 cm1; 1H NMR
(400 MHz, CDCl3): 7.91–7.84 (m, 3H), 7.52–7.36 (m, 6H),
7.19–7.14 (m, 2H);13C NMR (100 MHz, CDCl3): 162.2 (d,
J = 244.4 Hz), 139.1, 136.63, 136.59, 133.7, 131.6, 131.5,
128.3, 127.8, 127.0, 126.1, 125.8, 125.7, 125.3, 115.3, 115.0;
MS (70 eV), m/z (%): 222.4 (74) [M]+, 221.1 (100).
1
(44%) of 3ha (3ha-1/3ha-2 = 53/47). H NMR (400 MHz,
CDCl3, ppm) 7.66 (s, 1H); MS (70 eV), m/z (%): 218.2
(100) [M]+.
We are grateful for the financial supports from Sichuan Provincial De-
partment of Education (11ZA108), National Natural Science Foundation of
China (21202109 and 21072140), Special Funds of Sichuan Normal Uni-
versity for Sharing the Large Precision Equipments (DJ2012-07,
DJ2011-16) and Sichuan Normal University.
1
(a) Medarde M, Maya ABS, Pérez-Melero CJ. Naphthalene com-
bretastatin analogues: Synthesis, cytotoxicity and antitubulin activity.
Enzyme Inhib Med Chem, 2004, 19: 521–540; (b) Xie X, Kozlowski
MC. Synthesis of the naphthalene portion of the rubromycins. Org
Lett, 2001, 3: 2661–2663; (c) Ukita T, Nakamura Y, Kubo A,
Yamamoto Y, Takahashi M, Kotera J, Ikeo T. 1-Arylnaphthalene
lignan: A novel scaffold for type 5 phosphodiesterase inhibitor. J
Med Chem, 1999, 42: 1293–1305; (d) Ward RS. Lignans, neolignans,
and related compounds. Nat Prod Rep, 1995, 12: 183–205; (e) Tru-
jillo JM, Jorge RE, Navarro E, Boada J. Lignans from Justicia hys-
sopifolia. Phytochemistry, 1990, 29: 2991–2993; (f) Seong BL, Han
6-Chloro-1-phenylnaphthalene (3ga-1) and 1-chloro-8-phen-
ylnaphthalene (3ga-2)